Skip to Content

Wilstart (antihemophilic factor / von willebrand factor) Disease Interactions

There are 6 disease interactions with Wilstart (antihemophilic factor / von willebrand factor):

Moderate

Antihemophilic factor (applies to Wilstart) cardiovascular complications

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII. Care should be exercised when using this agent in patients with cardiovascular risk factors.

Moderate

Antihemophilic factor (applies to Wilstart) inhibitory antibodies

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect

The formation of neutralizing antibodies (inhibitors) to Factor VIII may occur. Subsequent administration of either antihemophilic factor can result in anamnestic response and increased levels of inhibitor. Response to treatment with antihemophilic factor may be less than expected. Cross-reactivity between human and recombinant agents has been noted. It is recommended to carefully monitor patients for the development of factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled, perform an assay that measures factor VIII inhibitor concentration to determine if a factor VIII inhibitor is present. Clinical assessment of patient history, severity of bleeding and inhibitor level (history and current) is necessary.

References

  1. "Product Information. Koate-HP (antihemophilic factor)." Bayer, West Haven, CT.
Moderate

Antihemophilic factor (human) (applies to Wilstart) blood isoagglutinin

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect

Blood group isoagglutinins (anti-A and anti-B) are present in antihemophilic factor (human) at concentrations that may not be clinically significant when used to control minor bleeds. Monitoring of hematocrit and Coombs for signs of intravascular hemolysis and falling hematocrit is recommended in patients with blood groups A, B, or AB when large or frequently repeated doses of antihemophilic factor (human) are administered. Acute hemolytic anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia. Should this condition occur, leading to progressive hemolytic anemia, discontinue treatment and consider administering serologically compatible Type O red blood cells and providing alternative therapy.

References

  1. "Product Information. Koate-HP (antihemophilic factor)." Bayer, West Haven, CT.
Moderate

Antihemophilic factor (human) (applies to Wilstart) immunodeficiency

Moderate Potential Hazard, Moderate plausibility.

Because antihemophilic factor (human) is made from human blood, it may carry a risk of transmitting infectious agents. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during the manufacturing process. The risk of transmission of infectious agents cannot be eliminated completely. Some viruses, such as Parvovirus B19 virus (B19V) or hepatitis A (HAV), are particularly difficult to remove or inactivate. B19V may most seriously affect pregnant women and immune-compromised individuals. Physicians should be alert to the potential symptoms of B19V and HAV infections and should strongly consider administration of hepatitis A and hepatitis B vaccines to individuals receiving plasma derivatives. Potential risks and benefits of vaccination should be weighed by the physician and discussed with the patient.

Moderate

Antihemophilic factor/von Willebrand (applies to Wilstart) thromboembolic events

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder

Thromboembolic events have been reported in patients receiving antihemophilic factor/von Willebrand factor complex replacement therapy. Care should be exercised in the existence of known risk factors for thrombosis. Endogenous high levels of factor VIII have also been associated with thrombosis, but no causal relationship has been established. Caution is recommended and consider antithrombotic measures in all patients at risk who are receiving coagulation factor replacement therapy.

Moderate

Von Willebrand factor (applies to Wilstart) thromboembolic reactions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder

Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis. Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.

Wilstart (antihemophilic factor / von willebrand factor) drug interactions

There are 3 drug interactions with Wilstart (antihemophilic factor / von willebrand factor)

More about Wilstart (antihemophilic factor / von willebrand factor)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.